Profil
Patrick Loustau is President, Chief Executive Officer & Director at Granite Bio AG since 2025.
Formerly, Mr. Loustau was Senior Vice President-Global Commercialization at Bristol Myers Squibb Co. in 2014, President at Zafgen, Inc. from 2014 to 2016, and Senior VP-Global Marketing & Medical Affairs at Novo Nordisk A until 2010.
Education includes graduate studies at Université de Paris XI Paris Sud.
Aktiva positioner av Patrick Loustau
| Företag | Position | Start |
|---|---|---|
Granite Bio AG
Granite Bio AG BiotechnologyHealth Technology Operates as a biotechnology company which develops therapeutic antibodies | Verkställande Direktör | 2025-02-01 |
Tidigare kända positioner av Patrick Loustau
| Företag | Position | Slut |
|---|---|---|
| LARIMAR THERAPEUTICS, INC. | President | 2016-07-19 |
| BRISTOL-MYERS SQUIBB COMPANY | Företagsledare/Principal | 2014-04-01 |
| NOVO NORDISK A/S | Företagsledare/Principal | 2010-07-01 |
Patrick Loustaus utbildningar
Erfarenheter
Innehade positioner
Aktiva
Inaktiva
Börsnoterade företag
Privata företag
Relationer
Första gradens relationer
Företag kopplade till första graden
Man
Kvinna
Styrelseledamöter
Chefer
Kopplade företag
| Privata företag | 5 |
|---|---|
Bristol Myers Squibb Co.
Bristol Myers Squibb Co. Pharmaceuticals: MajorHealth Technology Manufactures and markets biopharmaceuticals products | Health Technology |
Novo Nordisk A/S
Novo Nordisk A/S Pharmaceuticals: MajorHealth Technology Manufactures and markets pharmaceutical products for diabetes care | Health Technology |
Zafgen, Inc.
Zafgen, Inc. BiotechnologyHealth Technology Operates as a biopharmaceutical company | Health Technology |
Université de Paris XI Paris Sud
Université de Paris XI Paris Sud Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Granite Bio AG
Granite Bio AG BiotechnologyHealth Technology Operates as a biotechnology company which develops therapeutic antibodies | Health Technology |
















